Rigel Pharmaceuticals, Inc., announced that it has entered into a definitive agreement to acquire the U.S. rights to GAVRETO from Blueprint Medicines Corporation. GAVRETO...
Rigel Pharmaceuticals, Inc. announced a peer-reviewed publication of data in Blood Advances, which summarizes clinical results from the Phase 2 registrational study of REZLIDHIA™, a...
